NEW ORLEANS, May 17 /PRNewswire-FirstCall/ —
Actelion Ltd (SIX: ATLN) announced today that findings from
the REVEAL® (Registry to EValuate Early And Long-term PAH
Disease Management) Registry have confirmed the clinical utility of
the REVEAL risk score calculator, a new tool designed to predict
1-year survival in patients with pulmonary arterial hypertension
(PAH) according to data presented at the American Thoracic
Society’s (ATS) Annual International Conference. The predictive
tool was developed and validated in patients enrolled in REVEAL,
the largest prospective registry in PAH containing data from more
than 3,500 patients.
“The REVEAL risk score calculator provides an innovative
approach to better understand pulmonary arterial hypertension by
looking at a unique combination of variables, that together, can
help predict patient survival,” said Raymond L. Benza, M.D., Medical Director
of the Gerald McGinnis Cardiovascular of Advanced Heart Failure,
Transplantation, Mechanical Circulatory Support and Pulmonary
Hypertension Program, and Director of the Gerald McGinnis
Cardiovascular Institute Center for Research and Innovation at
Allegheny General Hospital, Pittsburgh. “We look forward to
obtaining more data from the REVEAL Registry that can be used as an
adjunct to the clinical experience and judgment of physicians who
treat this chronic and life-threatening disease.”
About “Use of REVEAL PAH Risk Score Calculator in Newly
Diagnosed Patients”
Data from 2,717 newly and previously diagnosed PAH patients
enrolled in REVEAL were used to develop a predictive tool from a
stepwise model based on nineteen variables, including WHO Group I
subgroup, mean right atrial pressure, pulmonary vascular
resistance
‘/>”/>